Wanhuida Intellectual Property
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyZhigang Zhu, Xiaoyang Yang, and Feng Zheng of Wanhuida Intellectual Property outline the intellectual property-related challenges Chinese enterprises face in pursuing growth through overseas expansion, and explain the steps that can help navigate the complexities -
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
-
Sponsored by Wanhuida Intellectual PropertyJicheng Yang and Jianhui Li of Wanhuida Intellectual Property draw on insights from CNIPA practice in discussing how different drafting approaches to crystal form patent claims impact protection scope and patent validity
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
-
Sponsored by Wanhuida Intellectual PropertyA ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property
